Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Bayesian multivariate linear mixed-effects models with varied association structures.

Statistical methods in medical research·2026
Same author

Managing Pompe Disease and Enzyme Replacement Therapy During Pregnancy: Challenges and Considerations.

European journal of neurology·2026
Same author

Quantitative Muscle MRI of the Lower Extremities Reveals Different Patterns of Involvement in Classic Infantile and Young Late-Onset Pompe Patients.

Journal of inherited metabolic disease·2026
Same author

Unfavorable cardiovascular risk profile without increased event prevalence in late-onset Pompe disease: an individually matched cohort study.

Orphanet journal of rare diseases·2026
Same author

Population Pharmacokinetic/Pharmacodynamic Modeling of Therapeutic Enzymes in Lysosomal Storage Diseases.

Clinical pharmacokinetics·2026
Same author

Antibody formation and efficacy of enzyme replacement therapy in adults with Pompe disease: Unlocking long-term insights.

Genetics in medicine : official journal of the American College of Medical Genetics·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
関連記事をすべて見る

関連する実験動画

Updated: Jun 28, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

ポンペの病はポンペの病である.

Ans T van der Ploeg1, Arnold J J Reuser

  • 1Department of Paediatrics, Division of Metabolic Diseases and Genetics, Erasmus MC, Sophia Children's Hospital, University Medical Centre, Rotterdam, The Netherlands. a.vanderploeg@erasmusmc.nl

Lancet (London, England)
|October 22, 2008
PubMed
まとめ
この要約は機械生成です。

ポンペ病は,リゾソームにグリコゲンの蓄積を引き起こす珍しい遺伝疾患です. 酵素置換療法は,この進行性代謝および筋肉疾患の治療選択肢を大幅に改善しました.

さらに関連する動画

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Tissue Triage and Freezing for Models of Skeletal Muscle Disease
05:58

Tissue Triage and Freezing for Models of Skeletal Muscle Disease

Published on: July 15, 2014

関連する実験動画

Last Updated: Jun 28, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Tissue Triage and Freezing for Models of Skeletal Muscle Disease
05:58

Tissue Triage and Freezing for Models of Skeletal Muscle Disease

Published on: July 15, 2014

科学分野:

  • バイオケミストリー バイオケミストリー
  • 遺伝学 遺伝学とは
  • 小児科は小児科です.

背景:

  • ポンペ病は,グリコゲン貯蔵疾患II型または酸マルターゼ欠乏症とも呼ばれ,汎民族的自己相性後退性代謝障害である.
  • 酵素酸アルファ-グルコシダースの欠乏によって特徴づけられ,ライソソーム内のグリコゲンの蓄積につながります.
  • この一般化されたグリコゲン貯蔵は複数の臓器系に影響を与え,主に筋肉機能に影響を与え,進行的な運動性と呼吸器系の問題につながります.

研究 の 目的:

  • ポンペ病の病理生理学,臨床的スペクトル,診断方法を含むポンペ病の総合的な概要を提供すること.
  • 患者のケアにおける重要な進歩,特に酵素置換療法 (ERT) の開発と承認を強調する.
  • 病気のメカニズムと新たな治療戦略に関する最新の洞察を議論する.

主な方法:

  • ポンペ病に関する既存の文献のレビュー,遺伝学,生化学,臨床研究を含む.
  • 酵素置換療法 (アルグルコシダゼアルファ) の歴史的開発と規制承認の分析.
  • ポンペ病の管理における現在の臨床慣行と将来の方向性の議論.

主要な成果:

  • ポンペ病は,幼児期から成人期までの個人に影響を及ぼし,広範囲な臨床的スペクトルを提示し,心臓の縮が幼児期の形態の特徴である.
  • 2006年に承認されたアルグルコシダゼアルファによる酵素置換療法 (ERT) の出現は,疾患の進行を緩和する手段を提供することで,治療の景観を変えました.
  • この治療の進歩は,ポムペの病気を,治療法が利用可能なリソソーム貯蔵障害の増大するグループに配置しています.

結論:

  • 酵素置換療法は,ポンペ病の管理における大きなブレークスルーであり,患者のアウトカムを大幅に改善しています.
  • 病気の病理生理学と治療的介入に関する継続的な研究は,ポンペ病の患者のケアをさらに改善するために不可欠です.
  • 患者のケアと結果を最適化するために,診断と管理に関する最新の知識の啓発と普及は不可欠です.